A 38-year-old woman with known Hashimoto's thyroiditis on stable levothyroxine 75 mcg daily presents with recurrent miscarriages (3 losses in the first trimester over 18 months). Her current TSH is 1.2 mIU/L (normal 0.4–4.0) and free T₄ is 1.1 ng/dL (normal 0.8–1.8). She is planning to conceive again. What is the most appropriate adjustment to her thyroid management?

Explanation

## Thyroid Management in Pregnancy and Recurrent Miscarriage ### Clinical Context: Hypothyroidism and Pregnancy Loss **Key Point:** Thyroid dysfunction—even subclinical—is associated with recurrent miscarriage, infertility, and adverse fetal outcomes. Women with hypothyroidism planning pregnancy require **tighter TSH control** than non-pregnant women. ### Why Increase to 88 mcg (Target TSH 0.5–2.5)? 1. **Pregnancy-Specific TSH Targets:** - **Non-pregnant women:** TSH 0.5–2.5 mIU/L - **Preconception (women planning pregnancy):** TSH 0.5–2.5 mIU/L (some guidelines suggest <2.0) - **First trimester:** TSH <2.5 mIU/L (some guidelines <2.0) - **Second/third trimester:** TSH <3.0 mIU/L 2. **Why This Patient Needs Adjustment:** - Current TSH 1.2 mIU/L is technically in range but may be **suboptimal for conception** - Recurrent first-trimester losses in a woman with autoimmune thyroiditis suggest **inadequate thyroid hormone reserve** - Pregnancy increases thyroid hormone requirements by 25–50% due to: - Increased volume of distribution - Increased renal clearance of iodine - Placental deiodinase activity - Increased TBG (thyroxine-binding globulin) from estrogen 3. **Dose Adjustment Strategy:** - Increase by 12.5–25 mcg (75 → 88 mcg) to achieve TSH 0.5–2.5 mIU/L - Recheck TSH in 6–8 weeks - Once pregnant, increase dose by 25–30% immediately (e.g., 88 → 100 mcg) and recheck TSH at 4–6 weeks **High-Yield:** **Preconception TSH optimization** is frequently tested in NEET PG. The concept that "normal TSH" in non-pregnant women may be insufficient for pregnancy is a common trap. ### Why Not the Other Options? | Option | Why Incorrect | |--------|---------------| | Increase to 100 mcg, target TSH <0.1 | TSH <0.1 (suppressed) increases risk of atrial fibrillation and bone loss; not indicated unless treating thyroid cancer. Suppressive therapy is harmful in pregnancy. | | Maintain current dose | Current TSH 1.2 may be inadequate for conception; recurrent losses suggest need for optimization. Waiting for pregnancy to adjust is suboptimal. | | Switch to T₃ monotherapy | No evidence supports T₃ monotherapy for pregnancy outcomes; T₄ monotherapy is standard. T₃ has a short half-life and causes fluctuations unsuitable for pregnancy. | **Mnemonic:** **TRIM** = **T**hyroid optimization, **R**ecurrent loss, **I**ncrease dose, **M**onitor TSH ### Mechanism: Why Thyroid Matters in Early Pregnancy ```mermaid flowchart TD A[Inadequate maternal T4]:::outcome --> B[Reduced placental T3 production]:::outcome B --> C[Impaired fetal neurogenesis & organogenesis]:::outcome C --> D[First-trimester loss or neurodevelopmental delay]:::urgent E[Optimized TSH 0.5-2.5 preconception]:::action --> F[Adequate T4 reserve for pregnancy]:::outcome F --> G[Normal placental & fetal thyroid function]:::outcome G --> H[Successful pregnancy & normal neurodevelopment]:::outcome ``` **Clinical Pearl:** In India, where iodine deficiency is endemic in some regions, adequate iodine supplementation (150 mcg/day) should also be ensured in women planning pregnancy, in addition to levothyroxine optimization. [cite:Endocrine Society Clinical Practice Guidelines for Thyroid Disease in Pregnancy and Postpartum; Harrison 21e Ch 405]